Worawattanakul M, Rhoads J M, Lichtman S N, Ulshen M H
Department of Pediatrics, University of North Carolina, Chapel Hill 27599-7220, USA.
J Pediatr Gastroenterol Nutr. 1999 Jan;28(1):37-40. doi: 10.1097/00005176-199901000-00010.
Abdominal migraine is a syndrome characterized by recurrent stereotypic episodes of paroxysmal abdominal pain and nausea and/or vomiting with wellness between episodes. It is often associated with a positive family history of migraine and no other apparent underlying disease. The purpose of this study was to report in patients diagnosed with abdominal migraine the outcome, the effect of prophylactic treatment, and the duration of treatment.
The records of 53 patients who underwent treatment after a diagnosis of abdominal migraine were retrospectively reviewed. Responses to treatment were graded as excellent (cessation of recurrent abdominal pain), fair (persistence of symptoms but milder and less frequent), or poor (no response). Follow-up data were available in 38 patients. Twenty-four patients were treated with propranolol and 12 with cyproheptadine. Four were not treated because of mild and infrequent symptoms.
Among the children treated with propranolol, 18 (75%) had an excellent response, 2 (8%) had a fair response, and 4 (17%) had no response. In those treated with cyproheptadine, 4 (33%) had an excellent response, 6 (50%) had a fair response, and 2 (17%) had no response. Patients were instructed to continue medication for 6 months or until cycles had stopped. However, 11 of 24 patients (46%) in the propranolol group took medication for less than 6 months and the remaining patients from 6 months to 3 years. Six patients in the cyproheptadine group (50%) took medication less than 10 months and the remaining patients for 10 months to 3 years.
Patients with abdominal migraine may benefit from prophylactic treatment with propranolol or cyproheptadine.
腹型偏头痛是一种以反复发作的阵发性腹痛、恶心和/或呕吐为特征的综合征,发作间期无症状。它常与偏头痛家族史阳性相关,且无其他明显的潜在疾病。本研究的目的是报告诊断为腹型偏头痛的患者的治疗结果、预防性治疗的效果及治疗持续时间。
回顾性分析53例诊断为腹型偏头痛后接受治疗的患者的病历。治疗反应分为优(反复腹痛停止)、良(症状持续但较轻且发作频率较低)或差(无反应)。38例患者有随访数据。24例患者接受普萘洛尔治疗,12例接受赛庚啶治疗。4例因症状轻微且发作不频繁未接受治疗。
在接受普萘洛尔治疗的儿童中,18例(75%)反应优,2例(8%)反应良,4例(17%)无反应。在接受赛庚啶治疗的患者中,4例(33%)反应优,6例(50%)反应良,2例(17%)无反应。患者被要求持续用药6个月或直至发作周期停止。然而,普萘洛尔组24例患者中有11例(46%)用药时间不足6个月,其余患者用药时间为6个月至3年。赛庚啶组6例患者(50%)用药时间不足10个月,其余患者用药时间为10个月至3年。
腹型偏头痛患者可能从普萘洛尔或赛庚啶预防性治疗中获益。